New data on Olanzapine LAI from Medincell and Teva at Psych Congress 2026 The findings gave more insights into stabilization and long term treatment outcomes. Teva also shared new data on UZEDY®, a new treatment option employing Medincell’s proprietary BEPO® technology. Teva will license the technology in the SteadyTeq™ platform. The results were presented at Psych Congress 2026 in New Orleans, Louisiana. It took place Sept. 15-19.
A new post hoc analysis of the Phase 3 SOLARIS trial was presented. A trial of an investigational once-monthly subcutaneous olanzapine LAI. It is under investigation for the treatment of adults with schizophrenia. The latest analyzes looked at the long-term stability and effectiveness of treatments. 56% of participants achieved stabilization during the long-term treatment period. Among those stabilized, only 4 percent subsequently relapsed.
In addition, 21% of those who received treatment for at least six months achieved remission based on the study’s criteria. These results provided additional information on long-term treatment outcomes. The new analyzes also looked at possible treatment-switching strategies. The strategies included patients switching from oral or short-acting injectable olanzapine regimens. Thus, the data provided insight into how Olanzapine LAI could aid treatment transitions. The results also reinforced existing evidence from the Phase 3 SOLARIS trial.
Olanzapine LAI Remains Under Regulatory Review
Olanzapine LAI remains an investigational treatment at this stage. It has not received approval from any regulatory authority. In the United States, the treatment remains under regulatory review. The U.S. Food and Drug Administration is expected to issue a PDUFA decision. The decision is expected during the fourth quarter of 2026. Until then, Olanzapine LAI remains investigational.
The review for regulation occurs after the Phase 3 development program. The latest findings provide more information on stabilization, remission, relapse and treatment switching. At the same time, Teva offered more real-world evidence for UZEDY®. The data looked at continuity of care for adults with schizophrenia. The analysis compared UZEDY® to several long-acting injectable antipsychotics. It also looked at healthcare resource use in patients who were treated.
The results demonstrated positive treatment continuity of UZEDY® in adult patients with schizophrenia. Another analysis showed less healthcare resource consumption than once-monthly paliperidone palmitate. These findings provide a real-world context to the clinical data presented at the event. They also provide further insights into treatment patterns in schizophrenia care.
UZEDY® Data Expand Evidence in Schizophrenia and Bipolar I Disorder
Teva also presented analyzes in adults with bipolar I disorder. Patients who switched from oral antipsychotics to UZEDY® were included in the investigation. This analysis provides another area of evidence for UZEDY® treatment. It also considers the effects of treatment following conversion from oral antipsychotic therapy. The presentations covered clinical trial and real-world evidence together. The data covered various aspects of care for schizophrenia and bipolar I disorder.
Olanzapine LAI results : Stabilization and long-term efficacy. They also thought about how patients might be moved between different treatments. However, UZEDY® analyzes focused on treatment continuity and healthcare utilization of resources. The studies also enrolled patients with bipolar I disorder. Both treatments utilize Medincell’s proprietary BEPO® technology. The technology is licensed to Teva as SteadyTeq™.
The latest presentations thus highlighted several areas of ongoing research. They included long term treatment, remission, relapse, switching strategies and real world outcomes. These updated findings were presented by Teva at Psych Congress 2026. The event provided new data on investigational and existing therapeutic approaches.
The Olanzapine LAI program is still under regulatory review. Meanwhile, more UZEDY evidence is added to the real-world data available. The presentations collectively gave new clinical and real-world data from Teva. Treatment of schizophrenia. Treatment of bipolar I disorder. The new Olanzapine LAI analyzes add to the evidence from the Phase 3 SOLARIS trial. The UZEDY® results add more information from real-world treatment settings.
Explore Health Tech Insiders for the latest medical innovations and reliable strategic insights driving the future of technology-driven healthcare transformation.
News Source: Businesswire.com
